Sax Wealth Advisors LLC Decreases Stock Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Sax Wealth Advisors LLC trimmed its position in HCA Healthcare, Inc. (NYSE:HCA) by 16.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 996 shares of the company’s stock after selling 191 shares during the period. Sax Wealth Advisors LLC’s holdings in HCA Healthcare were worth $299,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. acquired a new stake in HCA Healthcare in the second quarter worth about $33,000. Legacy Investment Solutions LLC purchased a new stake in HCA Healthcare during the 3rd quarter worth approximately $39,000. Canoe Financial LP purchased a new position in shares of HCA Healthcare in the third quarter worth $41,000. Capital Performance Advisors LLP acquired a new position in shares of HCA Healthcare in the 3rd quarter valued at $41,000. Finally, Northwest Investment Counselors LLC acquired a new stake in HCA Healthcare during the 3rd quarter worth about $44,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Insider Activity

In related news, insider Erol R. Akdamar sold 2,900 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the sale, the insider now directly owns 6,843 shares in the company, valued at approximately $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. This represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.

HCA Healthcare Trading Up 0.4 %

Shares of HCA Healthcare stock opened at $310.60 on Friday. The firm’s 50-day moving average price is $316.69 and its 200 day moving average price is $352.78. HCA Healthcare, Inc. has a twelve month low of $278.50 and a twelve month high of $417.14. The firm has a market capitalization of $78.68 billion, a PE ratio of 13.95, a P/E/G ratio of 1.03 and a beta of 1.64. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 27th. Shareholders of record on Friday, December 13th were issued a $0.66 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.85%. HCA Healthcare’s payout ratio is currently 11.85%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Wells Fargo & Company downgraded HCA Healthcare from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $400.00 to $320.00 in a report on Monday, November 25th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $380.00 price objective on shares of HCA Healthcare in a research note on Tuesday, December 17th. Barclays cut their price target on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Raymond James downgraded HCA Healthcare from an “outperform” rating to a “market perform” rating in a research note on Friday, November 22nd. Finally, TD Cowen lowered their price objective on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, HCA Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $385.27.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.